Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3402 + Tremelimumab + Durvalumab in Advanced HCC
NCT06608940Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BC3402 in hepatocellular carcinoma (HCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Overall Response Rate. Planned start Nov 2025; status: withdrawn.
02
Drugs
BC3402
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06608940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608940.